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ABSTRACT 
Introduction 
We tested the European Organization for Research and Treatment of Cancer 
Quality of Life (EORTC QLQ-C30) summary score (SumSC) to detect changes 
in the HRQOL after Non-small-cell lung cancer (NSCLC) surgery and compared 
its performance to the traditional scales. 
Method 
EORTC QLQ-C30 data was obtained from 326 consecutive pre-operative 
patients submitted for anatomical lung resections for NSCLC.66 patients 
completed post-operative assessments 3 months after surgery. The data was 
analysed to evaluate the ability of the SumSC compared to the traditional scales 
to (1) preoperatively differentiate between clinical groups; (2) detect post-op 
changes and to (3) compare pre and post-op changes in clinically different 
groups.The importance of perioperative changes was measured by calculating 
the effect size (ES). 
Results 
Of the 326 patients, those older than 70 years, with higher DLCO value and 
Performance Status (PS1 had a significantly better preoperative SumScore. 
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Physical function (PF) showed a large and significant decline (ES 0.91). Role 
and social function also showed a significant and medium decline (ES 0.62 and 
0.41). 
Postoperatively some symptoms scales showed significant increases in the 
values, implying worse symptoms with the largest increase in dyspnoea (ES -
0.88). The change in General Health score (GH) was not significant after 
surgery (ES 0.26, p=0.062). 
The SumSc, decreased significantly postoperatively. In particular, medium or 
large postoperative declines of SumSc were observed in both males and 
females, in patients with lower FEV1, lower performance score, and in those 
older than 70 years. Interestingly the decline of SumSc was observed 
irrespective of the preoperative DLCO level. 
Discussion 
The Summary Score was more sensitive to changes in subjects' HRQOL, than 
the GH score. The SumSc can be used as a parsimonious and easy to 
interpreted patient-reported-outcome measure in multi-institutional database 
and future clinical trials. 
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SUMMARY BOX 
What is the key question? 
x Can the European Organization for Research and Treatment of Cancer 
Quality of Life Questionnaire-Core30 (EORTC QLQ-C30) summary 
score (SumSC) reliably detect changes in Health-Related (HRQOL) 
Quality of Life after Lung Cancer Surgery? 
What is the bottom line? 
x While our findings confirmed that HRQOL at the first post-surgical follow-
up is worse compared the preoperative values in lung cancer patients, 
the Summary Score is more sensitive to changes in subjects' HRQOL, 
than the General Health Score.  
Why read on? 
x We confirmed that is feasible and reliable to use the EORTC QLQ-C30 
summary score in a lung cancer surgical cohort. It will be a unique 
HRQOL index in clinical practice, to better inform patients about 
postoperative outcomes, and in clinical trial where it can be used as a 
parsimonious and easy to interpreted patient-reported-outcome 
measure. 
 
 
 
 
 
5 
 
1. INTRODUCTION 
The impact of surgery on quality of life after surgical treatment for Non-Small 
Cell Lung cancer (NSCLC) is one of the most common concerns expressed by 
patients during the preoperative counselling(1). However, as demonstrated by 
a recent survey among members of the European Society of Thoracic 
Surgeons (ESTS), only few centres across Europe are routinely collecting 
these data during the perioperative period (2). 
The perioperative fast-tracked management of lung cancer surgical candidates 
has streamlined the patient care but has reduced the time available for the 
patient to complete questionnaires. Surgical multi-institutional databases have 
been advocated to improve NSCLC care across countries and International 
Societies have agreed to standardize definitions and variables (3). 
Nevertheless, patient-reported outcomes (PROs) are still missing from these 
databases, leaving this evidence to small institutional studies. One reason for 
this paucity of data about PROs is the lack of recommendation on the 
instruments to use or the presence of multiple scores generated by each survey, 
each associated with several and different dimensions of Health-related-
Quality-of-Life (HRQOL) 
One important feature of a useful clinical database is the focus on a core set of 
standardized clinically relevant variables. Following this principle, the 
development of a single summary measure indicating an aggregate status of 
HRQOL is desirable. 
Here, we tested the hypothesis that the European Organization for Research 
and Treatment of Cancer Quality of Life Questionnaire Core30 (EORTC QLQ-
C30) summary score (SumSC) is more sensitive to detect changes in the 
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HRQOL three months after lung cancer surgery compared to the traditional 
QLQ-C30 scales. The specific objectives were (1) to evaluate if SumSc at 
baseline differentiates between clinically distinct groups and how this compares 
with the traditional scoring; (2) to investigate if the SumSc is reliable in detecting 
post-op change, and how the performance compares with traditional scores; 
and eventually (3) to compare these changes in the clinically different groups. 
 
2. MATERIALS AND METHODS 
Prospective data collection was performed on a convenience sample of 326 
patients who had undergone anatomic pulmonary resection for the treatment of 
lung cancer at the Leeds Cancer Centre, UK from April 2014 to September 
2016 and had completed preoperative Health-Related Quality of Life 
assessment. 66 patients completed the questionnaire at three months after 
treatment.  
The preoperative sample size number represents 47% of all patients operated 
for lung cancer during the same period in our unit. All the patients referred for 
histologically proven or with highly suspicion of lung cancer, were scheduled to 
be approached by our lung cancer specialist nurse during their preoperative 
appointments. As per NHS practice, all these patients are due to have a 
meeting with the lung specialist nurse prior surgery. The patients were asked 
to fill the baseline questionnaire in clinic and to give this back to the nurse or 
the doctor during the same appointment. Nevertheless, this was a service 
evaluation without a dedicated financial support and dedicated resource 
personnel. It relied on the voluntary work of a single lung cancer nurse specialist. 
When she was not available or engaged with another patient, other patients 
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were not approached and consented for the questionnaire. The response rate 
for the preoperative questionnaire was 98%. As no criteria were used to select 
patients for the preoperative questionnaire administration we believe the 
sample enrolled is representative of the entire cohort who received an operation 
for lung cancer during the same period. 
The small proportion of patients filling the postoperative data is due first of all, 
to fact that only people living in the local Leeds metropolitan area received the 
follow-ups in the Leeds Cancer Centre whereas other patients were followed 
up in other satellite hospitals in the region. Furthermore, considering that this 
study relied on the crucial voluntary support of lung specialist nurse, we 
acknowledge that in the first Survivorship Clinic appointment, not all the nurses 
were aware of the study and able to give the questionnaire to the patients. As 
we reported a high completion rate in this follow-up time point (90%), the small 
number of postoperative questionnaires is due mostly to patients not 
approached. 
To demonstrate the absence of possible selection bias, we run a comparison 
between the two groups. No statistical difference was noted in most of the 
clinical characteristics of all the patients completing the postoperative survey 
and those who completed only the baseline one. 
Patients were selected for operation according to current functional guidelines 
and after discussion during a multidisciplinary tumour board meeting (4). 
All patients were operated by consultants on the General Medical Council 
(GMC) specialist register in cardiothoracic surgery either through a muscle-
sparing thoracotomy (n=62) or video-assisted thoracoscopic approach (VATS; 
n=265) depending upon the surgical indications (stage, size and loca
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tumour). All patients had a systematic mediastinal lymph node dissection along 
with the lung cancer resection. 
Postoperative care followed standardized pathways of care and included as 
early as possible mobilization and oral food intake, intense chest physiotherapy 
and rehabilitation, deep venous thrombosis prophylaxis and chest pain control 
using a combination of patient-controlled analgesia and paravertebral infusion 
of local anaesthetic. The following baseline and surgical variables were 
screened for a possible association with HRQOL scores: age, sex, forced 
expiratory volume in 1 second (FEV1) expressed in percentage of predicted 
value, Eastern Cooperative Oncology Group performance score (PS), diffusing 
capacity of the lung for carbon monoxide (DLCO) expressed in percentage of 
predicted value. These variables have been associated with an increased risk 
of postoperative complications and consequently they are the most frequently 
factors investigated in lung cancer surgical patients (4-6). 
The study was reviewed by the Research and Innovation Department of our 
hospital, which classified it as service evaluation and therefore did not need 
formal NHS Research Ethics Committee review. 
 
 
2.1 Health-related-Quality-of-Life Assessment 
QOL was assessed by administering in a clinic environment for self-completion.  
The European Organization for Research and Treatment of Cancer Quality of 
Life Questionnaire (EORTC QLQ-C30), Version 3, within 2 weeks before the 
operation and at 3 months after the operation. All the questionnaires were given 
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to the patients by the Lung Cancer specialist nurses during the standard-care 
appointments. 
The EORTC QLQ-C30 is an internationally validated cancer-specific HRQOL 
questionnaire (7). The 30-item EORTC QLQ-C30 version 3.0 is composed by 
five multi-item function scales (physical [PF], role [RF], cognitive [CF], 
emotional [EF], and social [SF]), three multi-item symptom scales (fatigue [FA], 
nausea and vomiting [NV], and pain [PA]), six single-item symptom scales 
(dyspnea [DY], insomnia [SL], appetite loss [AP], constipation [CO], diarrhea 
[DI], and financial impact [FI]), and a two-item global quality of life scale (QL).  
The questionnaire has a 1-week time frame and uses a four-point response 
IRUPDWµµQRWDWDOO¶¶µµDOLWWOH¶¶µµTXLWHDELW¶¶DQGµµYHU\PXFK¶¶ZLWKWKHH[FHSWLRQ
of the global QL scale, which are scored on a scale from 1 (very poor) to 7 
(excellent).  
The scores range from 0 to 100 after linear transformation of the raw scores. A 
high score for a functional scale represents a high level of functioning (healthier), 
whereas a high score for a symptom scale represents a high level of 
symptoms/problems.  
2.3 Summary Score 
Recently, the EORTC Quality of Life Group recommended the use of the QLQ-
C30 summary score to supplement the 15-outcome profile generated by the 
QLQ-C30. The scoring algorithm for generating the QLQ-C30 summary score 
is available YLDWKHJURXS¶V:HEVLWHhttp://groups.eortc.be/qol. The SumSc has 
been tested in a large existing dataset for validity and responsiveness to 
change over time. The EORTC Quality of Life Group steering Committee tested 
the SumSc comparing it to the individual QLQ-C30 scales using pre-treatment 
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QLQ-C30 data (N: 3,282) and conducting a confirmatory factor analysis. They 
also tested the seven HRQOL higher order measurement models evaluated by 
Gundy et al (8, 9). The use of a single score describing sensibly the HRQOL in 
clinical practice, will facilitate the routine collection of PROs and consequently 
their adoption in health-applied research. Preliminary data of a joint Society of 
Thoracic Surgeons (STS) and ESTS lung cancer surveillance survey, have 
shown as the HRQOL collection is still underrepresented across the two 
continents five years after surgery(10). 
The SumSc is calculated from the mean of 13 of the 15 QLQ-C30 scores (the 
Global Quality of Life score and the Financial Impact score are excluded).  
Prior to calculating the mean, the symptom scales need to be reversed to obtain 
a uniform direction of all scales. The summary score should only be calculated 
if all of the required 13 scale scores are available (using scale scores based on 
the completed items, provided that at least 50% of the items in that scale have 
been completed (11, 12).  
2.4 Statistical analysis 
Descriptive analysis 
All quality of life scores were calculated according to the scoring manual (11). 
The summary score was calculated according to Giesinger et al. (9), which led 
to a single score ranging from 0 (worst) to 100 (best). Descriptive statistics 
included counts and percentages, medians and inter-quartile ranges. Normality 
of distribution of numeric variables (including the QoL scores) was assessed by 
the Shapiro Wilk test.  
 
Post-operative Change analysis 
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Before-after differences of QoL scales at 3 months were calculated using the 
Wilcoxon matched pairs rank-sum test. In addition, the importance of the 
perioperative changes in QoL scales was measured by calculating the effect 
size (mean change of the variable divided by its baseline standard deviation) 
(13, 14). Effect sizes of 0.2, 0.5 and 0.8 indicate a small, medium and large 
difference, respectively. The sign before the effect size indicates the direction 
of the difference (a positive sign means that the preoperative value is greater 
than the postoperative one). Between groups calculations made use of the 
independent t-test for numeric variables with normal distribution or of the 
Wilcoxon rank-sum test for those without normal distribution. Categorical 
variables were compared by using the Chi-square test or the )LVKHU¶VH[DFWWHVW
(in case of 10 or fewer variables in at least one of the cells). All analyses were 
exploratory in nature, thus significant p-values (p < 0.05) should not be 
interpreted as confirming a priori hypothesis. The analysis was performed on 
Stata 12.0 statistical software (Stata Co., College Station, TX).  
 
 
3. RESULTS 
The characteristics of the 326 patients included in the study are shown in table 
1.  
Table 2 shows the comparison between the patients with both preoperative and 
postoperative HRQOL assessments and those who have completed only the 
preoperative questionnaire. In the group of patients who completed the 
postoperative questionnaire, we found 3-fold higher proportion of operations 
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performed through thoracotomy (p=0.008) and a greater proportion of females 
(p=0.002). 
 
3.1 Baseline HRQOL and analysis of SumSc 
Table 3 shows the preoperative values of the individual QoL scores.  
The median preoperative SumSc in the entire population was 87.4 (IQR 77.2-
93.6).  
One hundred and forty-seven patients (45%) were older than 70 years of age. 
Compared to younger patients they had a higher (better) preoperative SumSc 
(90.6, IQR 79.9-94.9 vs. 85.3, IQR 74.0-92.5; p=0.003). 
Twenty-four patients (7.4%) had a preoperative performance score (PS) 
assigned by clinicians, greater than 1 (2 or 3). The Eastern Cooperative 
Oncology Group (ECOG) Performance Score measures how the disease 
LPSDFWV D SDWLHQW¶V GDLO\ OLYLQJ DELOLWLHV UDWLQJ WKLV IURP  IXOO\ DFWLYH WR 
(death)(15). 
These patients had a worse preoperative SumSc compared to patients with 
performance score of 0 or 1 (74.7, IQR 57.7-92.2 vs. 87.8, IQR 77.8-94.0; 
p=0.004). 
One hundred and fifty-three patients (46.9%) had a preoperative DLCO lower 
than 70% predicted value. These patients had a lower baseline SumSc 
compared to those with higher DLCO (85.7, IQR 74.9-92.1 vs. 89.7, IQR 79.8-
94.6; p=0.019). 
There were no differences of preoperative SumSc between male and female 
patients (89.7, IQR 75.8-94.0 vs. 86.5, IQR 77.4-93.5; p=0.38) or between 
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patients with FEV1 lower than 70% and those with higher FEV1 (86.4, IQR 
76.3-93.6 vs. 87.6, IQR 77.2-93.6; p=0.62).  
3.2 Perioperative Changes Analysis 
Patients eligible for the postoperative assessment were those who were 
referred to the Leeds Survivorship Clinic which is including only patients coming 
from the Leeds metropolitan area and not needing additional postoperative 
therapies. Of those, sixty-six patients completed the EORTC QLQ C30 
questionnaire three months after the operation (90% completion rate).  
Table 4 shows the perioperative changes of QoL scales and SumSc in this 
population. PF showed a large and significant decline at three months. RF and 
SF showed a significant and medium decline (effect sizes 0.62 and 0.41, 
respectively) (effect size 0.91).  
Some of the symptom scales (FA, PA, DY, FI) showed a postoperative 
significant increase in their values (worse symptoms). In particular, DY was the 
one with the largest increase (effect size -0.88). 
The change in General Health score (GH) was not significant after surgery 
(effect size 0.26, p=0.062). At variance with the GH, the SumSc decreased 
significantly at three months (effect size 0.48, p<0.001).  From a clinical point 
perspective, we are expecting a decrease in HRQOL especially during the first 
three months after operation(5). 
 
 
3.3 Subgroups Analysis 
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Table 5 shows the perioperative changes of SumSc in different groups of 
patients with or without risk factors for surgery. Caution should be used when 
interpreting these results for the small numbers of patients in each subgroup.  
In particular, medium or large postoperative declines of SumSc were observed 
in both males and females, in patients with lower FEV1, lower performance 
score, and in those older than 70 years of age. Finally, a similar postoperative 
medium decline of SumSc was observed irrespective of the DLCO level. 
 
 
 
4. DISCUSSION 
The Cardio-Thoracic speciality has been one of the first ones to introduce and 
champion the risk-adjusted outcome analysis for monitoring and improving 
quality of care (16, 17). However, there is an increasing interest in investigating 
WKHSRVVLEOHLQFOXVLRQRIWKHSDWLHQW¶VSHUVSHFWLYHLQWKHVHVFRUHV(18). The first 
VWHS LQ WKLV ILHOG LV WR LGHQWLI\ WKH PRVW DSSURSULDWH LQGLFDWRU RI WKH SDWLHQWV¶
voice: the SumSc can represent a valuable candidate for this, reflecting the 
SDWLHQWV¶ VHOI-assessment of their daily life after a surgical operation for lung 
cancer. 
4.1 Main findings 
In our cohort of surgical lung cancer patients, HRQOL decreased three months 
after the operation. This decline varied through the scales with meaningful 
effects confirmed in the Social, Physical and Role Functioning and in the 
Dyspnoea symptom score. The General Health score, which reflects the 
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SDWLHQW¶V FRQVLGHUDWLRQ RI their quality of life, did not change significantly 
between pre-and post-treatment. 
Our results showed, on the other hand, that the EORTC Summary Score was 
significantly reduced after surgery. 
We were also able to show that SumSc detected important differences between 
subgroups of patients confirming the existing evidence. The analysis of 
subgroups of patients considered clinically at high risk for surgery, although 
limited in numbers, showed interesting results confirming that objective 
variables cannot be considered as surrogates of patient-reported quality of life. 
For example, Gender and FEV1 were factors not associated with different 
preoperative QoL scores. Patients with lower DLCO, an age older than 70 years 
or a PS>1 reported lower baseline values of SumSc. However, as 
demonstrated in the past (6, 19), DLCO was not associated with a greater QoL 
decline according to the SumSc analysis. 
 
4.2 Findings in the existing literature 
The global domain of HRQOL is a concept of particular interest especially from 
WKHSDWLHQW¶VSRLQWRIYLHZDVWKLVLVWKHGRPDLQ, which they are always referring 
during the surgical consultation. However, it must contain most of the 
FRPSRQHQWVRIWKHSDWLHQW¶VOLIHFRUUHFWO\ZHLJKWHG 
Giesinger and colleagues have already shown that the validity and 
responsiveness of the EORTC QLQ-C30 SumSc is equal or even superior to 
the original underlying QLQ-C30 scales scores (9). Most recently, the SumSc 
has also demonstrated good ability to detect changeVLQVXEMHFWV¶TXDOLW\RIOLIH
among patients with unresectable hepatocellular carcinoma(20). Similar to our 
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result, the authors showed that the SumSc performed better than the Global 
Health scale of QLQ-C30 especially in showing changes over time. 
Several investigations have described significantly reduction in HRQOL after 
surgical resection for lung cancer. This decrease is particular evident in the first 
postoperative period, to improve, although not completely to preoperative levels, 
in the following months (5, 21).  The SumSc in our series confirmed this trend 
in conjunction with most of the single functioning and symptom scales, while 
the General Health score GLGQ¶W 
Regarding the age-related sub analysis, several studies have demonstrated 
that age is not a major determinant of quality of life after lung resection for 
cancer. Ferguson and colleagues found no difference in the postoperative QOL 
scores between patients younger or older than 70 (6). Burfeind and colleagues 
used the EORTC QLQ-C30 instrument in a prospective, longitudinal study to 
assess their lobectomy patients and found no significant difference between 
older (>70 years) and younger cohorts (22).  
The SumSc in our population, showed a large decline after three months from 
the operations only in patients older than 70 years, probably taking into 
consideration all the detailed DVSHFWVRIWKHROGHUSDWLHQW¶VTXDOLW\RIOLIH, which 
are not easily detected by answering to the generic question.  
Our results show that the gender-specific analysis does not follow the trend 
previously described in thoracic oncology surgery, for example  Chang  et al. 
reported gender was a significant determinant of the HRQoL aspects of 
physical, emotional and cognitive functioning(23). 
The SumSc in our series was largely reduced in patient with forced expiratory 
volume in the first second (FEV1) lower than 70% of predicted, although at the 
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baseline assessment there were no difference between these two groups. In 
our previous study of 220 patients investigated with the SF-36 questionnaire 
before and after surgery, we selected patients with chronic obstructive 
pulmonary disease (COPD) to compare their HRQOL with a case-matched 
population of patients with normal respiratory function. We were not able to find 
differences between the groups in any of the preoperative and postoperative 
physical and mental QoL scales(24). Ferguson and co-authors, using the 
EORTC QLQ-C30 and LC-13 module, found that FEV1 as a consistent 
predictor of physical function, role function, fatigue, pain, and dyspnoea. 
However, this cross-sectional study has a much longer follow-up of (2.7 year), 
whether our analysis was focused only on the very short-term (6). 
 
In US the first attempt to incorporate PROs in the Society of Thoracic Surgeons 
database with the National Institutes of Health Patient Reported Outcome 
Measurement Information System (PROMIS) has demonstrated the feasibility 
of the future integration in lung cancer patients records(25). The American 
College of Chest Physicians (ACCP) has made the quality of life data collection 
a class 2B recommendation for all lung cancer surgery patients(26). We need 
now to overcome the difficulty of streamlining this collection in the daily practice, 
and to find the best standardized PROMs to be included in these already 
enormous clinical databases. 
 
 
4.3 Limitations: 
This study has some limitations. 
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- First of all, we collected a limited number of postoperative assessments. This 
is due to logistical reasons with only patients who live in the surrounding area 
being followed up in our Hospital, where the preoperative assessment has 
taken place. Furthermore, patients eligible for the first postoperative 
assessment were only patients who did not require postoperative 
chemotherapy or radiotherapy and were referred to Leeds Survivorship clinic. 
We cannot rule out that the inclusion of all the patients may affect our results. 
However, the characteristics of the patients who did not participate in the 3 
months assessment were similar to those included in the analysis except for a 
lower proportion of VATS procedures and a predominance of female patients 
(Table 2).  
-The results of this study showed a difference between perioperative changes 
detected by GHS and SumSc. Our interpretation of superiority of SumSc may 
be challenged by future studies comparing the EORTC SumSc with other 
corresponding summary scores derived from other types of questionnaires 
(revealing a type I error in our study). Unfortunately, we were not able to 
administer to the same patients more than one questionnaire. As already 
shown in previous investigations(27) the administration of multiple QoL 
questionnaires evaluating similar concepts or domains may be too time 
consuming and stressful for the patient and introduce other biases.  
 
- Most of the operations were performed using VATS. The minor incidence of 
the post-thoracotomy pain especially in the early postoperative period has been 
recently reported in a large randomized trial comparing the two surgical 
approaches (28). 
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We acknowledge that it would be interesting to verify whether similar results 
would be found analysing a population with a larger proportion of thoracotomies.  
- We included only anatomical lung resections in our analysis. Future 
investigations are needed to explore the use of a SumSc with different surgical 
operations for lung cancer as wedge resections or with stages requiring 
postoperative additional therapies. 
-Finally, our study is limited to the three months follow-up. We have chosen this 
timeframe as this is when the major changes in HRQOL have been described 
and also to reduce the attrition rate. However, future investigations are 
warranted to evaluate the SumScore performance after three months from 
surgery. 
 
4.4 Conclusions: 
The Summary Score was more sensitive to changes in subjects' HRQOL, than 
the General Health Score. As suggested by the EORTC Quality of life group, 
the SumSc can avoid problems with potential type I errors that arise because 
of multiple testing when making comparisons based on the 15 outcomes 
generated by this questionnaire. In addition, the use of the QLQ-C30 summary 
score can reduce sample size requirements in clinical trials were HRQOL is a 
primary endpoint. In conclusion, our results suggest that the SumSc can be 
used as a parsimonious and easy to interpreted patient-reported-outcome 
measure in multi-institutional database and future clinical trials. 
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